Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors.
1/5 보강
Clinical responses of colorectal cancer (CRC) treatments vary considerably due to the heterogeneity of tumor microenvironment (TME), where intratumoral microbiota may reshape the unique inflammation i
APA
Dai CS, Qi TT, et al. (2025). Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors.. iScience, 28(12), 114202. https://doi.org/10.1016/j.isci.2025.114202
MLA
Dai CS, et al.. "Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors.." iScience, vol. 28, no. 12, 2025, pp. 114202.
PMID
41446733 ↗
Abstract 한글 요약
Clinical responses of colorectal cancer (CRC) treatments vary considerably due to the heterogeneity of tumor microenvironment (TME), where intratumoral microbiota may reshape the unique inflammation imprints. However, its complex mechanistic underpinnings remain incompletely elucidated. Herein, we sought to delineate the critical role of intratumoral microbiota in potentiating combination therapeutics against CRC. By comparing germ-free (GF) and specific pathogen-free (SPF) mouse models of 33 potential CRC treatments, we screened out capecitabine-MIH4 (anti-PD-1 antibody) combination regimen significantly augmented by intratumoral microbiota in tumor regression. The enrichment of enterotoxigenic induced by Capecitabine-MIH4 was concomitant with elevated microbial sphingosine-1-phosphate, which further up-regulated tumoral PD-L1 expression by enhancing histone deacetylation at the locus. This activation ultimately led to effector memory T cell expansion and exhausted T cell subset reduction within TME. To conclude, these findings highlight microbial sphingolipids as potential predictive biomarkers for strategies of targeting intratumoral microbiota in CRC management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy.